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of Chinese Academy of Sciences, Beijing and 5) Basic Medical Institute of Nanchang University, Nanchang, ChinaAbstractViral quasispecies analysis is important for basic and clinical research. This study was designed to detect hepatitis B virus (HBV) genome-wide
mutation proﬁling with detailed variant composition in individual patients, especially quasispecies evolution correlating with liver disease
progression. We characterized viral populations by massively parallel pyrosequencing at whole HBV genome level in 17 patients with
advanced liver disease (ALD) and 30 chronic carriers (CC). An average sequencing coverage of 2047× and 687× in ALD and CC groups,
respectively, were achieved. Deep sequencing data resolved the landscapes of HBV substitutions and a more complicated quasispecies
composition than previously observed. The values of substitution frequencies in quasispecies were clustered as either more than 80% or
less than 20%, forming a unique U-shaped distribution pattern in both clinical groups. Furthermore, quantitative comparison of mutation
frequencies of each site between two groups resulted in a spectrum of substitutions associated with liver disease progression, and among
which, C2288A/T, C2304A, and A/G2525C/T were novel candidates. Moreover, distinct deletion patterns in preS, X, and C regions
were shown between the two groups. In conclusion, pyrosequencing of the whole HBV genome revealed a panorama of viral
quasispecies composition, characteristics of substitution distribution, and mutations correlating to severe liver disease.
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F. Li and D. Zhang contributed equally to the articleIntroductionHepatitis B virus (HBV) may cause chronic infection that persists
for decades in patients, leading to severe clinical liver diseases,
especially liver cirrhosis (LC) and hepatocellular carcinomaMicrobiol Infect 2015; 21: 280–287
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.10.007(HCC) [1]. The high mutation rate of HBV is responsible for
highly diverse viral strains containing substitutions and indels [2].
The complexity of HBV quasispecies has been believed to
improve viral adaption to host environment changes [3].
Great efforts have been made to identify the viral mutations
related to LC or HCC. For instance, the well-known A1762T/
G1764A were reported to enhance viral replication and to
downregulate e antigen production [4]; deletion of preS and
COOH-terminal of X gene have been pointed out to
contribute to hepatocarcinogenesis [5,6]. However, in addition
to identifying novel variants associated with advanced liver
disease (ALD), dissecting the quasispecies changes along with
disease progression needs further efforts.
Massively parallel pyrosequencing allows high throughput
analysis of thousands of clonally ampliﬁed regions and is
therefore a powerful tool to study genetic diversity in viralious Diseases. Published by Elsevier Ltd. All rights reserved
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tivity to detect very rare variants with the frequency of 1% or
even less in quasispecies [8]. In HBV studies, such a strategy has
been applied to analyse minor antiviral resistance mutations
[9,10], G to A hypermutations in reverse transcriptase [11],
and mutation features in preC and YMDD motif [12]. Thus far,
these studies all focus on targeted HBV genes in speciﬁc clinical
groups, lacking of whole genome investigation, and quasispecies
evolution analysis in different stages of liver diseases.
Here we applied parallel pyrosequencing combined with bar-
coding strategy to dissect viral quasispecies at the whole HBV
genome level in samples of LC, HCC, and chronic carriers (CC).
These data provide a panorama of the viral mutations in either the
early onset of chronic infection or the end stage of liver disease
progression. Comparison of mutation proﬁles in these two stages
will help us determine the quasispecies evolution after long-term
infection and viral factors associatedwith the development of ALD.Patients and methodsSamples
We performed PCR ampliﬁcation and pyrosequencing on
samples from 17 patients with ALD (10 HCC and 7 LC) and 30
CCs. Plasma samples were collected in Jining Hospital for In-
fectious Diseases and Southwest Hospital of the Third Military
Medical University. All patients were given written informed
consent, and the ethics committees of all participating organi-
zations approved the study. Patients were diagnosed as CC, LC,
and HCC according to the Guideline on Prevention and
Treatment of Chronic Hepatitis B in China (2010) [13]. All CC
patients were no older than 18 years (Supplementary Table 1).
PCR design and amplicon pooling
Six primer pairs (Table 1) were initially designed to amplify the







1-F GGCGTTTTATCATCTTCCTCT 387–407 614 bp
1-R CAATTCGTTGACATACTTTCCA 979–1000
2-F ACATTGCCACAGGAACATA 904–922 645 bp
2-R GGAGTCCGCGTAAAGAGA 1531–1548
3-F ACCACCGTGAACGCCCA 1614–1630 631 bp
3-R ACAGTTTCTCTCCCAAAAGTAAG 2222–2244
4-F AGATCTCCTCGACACCG 1984–2000 642 bp
4-R GTCTCCTGTTTTCATTTACTG 2605–2625
5-F TCATTTGCAGGAGGACAT 2552–2569 630 bp
5-R GAGGTGGAGATAAGGGAGTA 3162–3181
6-F GGAGTGGGAGCATTCGG 3022–3038 622 bp
6-R TGAGGCATAGCAGCAGGA 411–428
7-F CGTCCTTTGTCTACGTCCCG 1415–1434 279 bp
7-R TCGGTCGTTGACATTGCTGA 1674–1693
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyconserved regions of HBV genotype B and C sequences; b)
Avoid regions of indel hotspots; c) Have high ampliﬁcation ef-
ﬁciency with barcode sequences at the end of primers; d)
Generate about 600 bp amplicon, which can be covered by two
bidirectional reads; e) Neighbouring amplicons have an overlap
of at least 40 bp. Since a region of 100 bp (nt 1531–1630) in X
gene would not be covered by the above design, a seventh
primer pair was later included (Table 1).
Each primer has an eight-nucleotide barcode at 5’ terminus
(Supplementary Table 1). In all, 34 barcodes were chosen from
the study of Hamady et al. [14]. For the construction of ALD
and CC sequencing pools, the ﬁrst six amplicons were mixed at
relatively equal concentrations using agarose gel electropho-
resis. The seventh amplicons for ALD and CC groups were
pooled and sequenced in a new run.
Pyrosequencing and data processing
Sequencing pools were puriﬁed using AMPure beads (Agen-
court Biosciences, Beverly, MA, USA) and sequenced by a 454
Genome Sequencer FLX system. For the ﬁrst six amplicons,
each pool was loaded in a quarter of a PicoTiter plate; and for
the seventh amplicons, each sequenced in one-eighth.
Reads with no mismatch in barcode sequence were separated
using Standard Flowgram Format (SFF) tools. The reference ge-
nomes ofHBV genotype B andCwere consensus sequences for all
complete genomes in the National Center for Biotechnology In-
formation database. Reads weremapped to the reference genome
and variants were called using the GS Amplicon Variant Analyzer
(version 2.3, Roche Applied Science). Variants in homopolymeric
regions were manually checked to assure their authenticity. For
substitution veriﬁcation, two amplicons in region 5 (the ﬁfth
primer pairs), with relatively low (514×) and high (3457×) pyro-
sequencing coverage, were cloned for Sanger sequencing
(Supplementary text).
Internal controls and hyperbola model construction
A plasmid containing whole HBV genome was previously con-
structed in our laboratory, from which a fragment ampliﬁed by
1-F/1-R primers with a speciﬁc barcode (Table 1) was used as
the internal control in the CC pool.
The internal controls in the ALD pool were ampliﬁed by 6-F/
6-R primers from three whole genome plasmids, including one
wild-type and two constructed preS2 deletions [15]. The three
types of control amplicons were pooled with ﬁve deﬁned
proportions (Supplementary Table 1). All amplicons were pu-
riﬁed and then quantiﬁed using PicoGreen (Invitrogen, Life
Technologies, Grand Island, NY, USA). Sequencing data of ALD
controls mixed with given ratios were used to construct a
model to evaluate the sequencing sensitivity. By randomly
retrieving reads from each internal control, simulations wereand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 280–287
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600 folds, to determine the coverage needed for detection of
mutations with various pooling frequencies.
The substitution error rate in our data was estimated as
1.7 × 10−4 according to the internal controls. Mismatch errors
were rarely observed with frequencies higher than 1% and
therefore, mutation rate at 1% in quasispecies was set as the
cutoff to eliminate technical artefacts.ResultsSequencing statistics of ALD and CC samples
We analyzed viral quasispecies composition at the whole HBV
genome level in 17 ALD and 30 CC samples. A total of 459 340
reads in ALD and 317 944 in CC were obtained, yielding an
average coverage of the whole genome at 2047 and 687, respec-
tively. The observed frequencies of internal controls ﬁt well with
the actual pooling ratios (Pearson correlation coefﬁcient = 0.994).
A hyperbola model Y = e6.44/X0.83 was resulted, which determines
the minimum sequencing coverage (Y) for detection of mutations
with a given frequency (X, X 1%, Supplementary Fig. 1A).
We deﬁne fm/quasi as the frequency of a substitution within
one subject (fm/quasi = the number of reads with mutations/
number of total reads covering that site in one sample). Based
on the hyperbola model, detection of mutations with fm/quasi at
1% and 5% require for minimum sequencing coverage of 625
and 165, respectively. Therefore, sites with insufﬁcient
sequencing coverage were precluded.
Genome-wide characterization of substitutions
Fig. 1 demonstrates a panorama of all HBV substitutions detected
in each sample. Complex quasispecies compositions were
observed in both ALD and CC groups. With fm/quasi higher than
1%, a mean of 157 substitutions in ALD samples and 50 in CC ones
(standard deviations were 67 and 17 for ALD and CC, respec-
tively) were detected across the HBV genome. In sequence con-
servation analysis, preS was the most variable in ALD, with an
average mutation rate (the mutation number/gene length (bp)) of
6.5%, and X gene had the highest mutation ratio in CC subjects
(average 1.8%). Meanwhile, preC was the most conserved in both
groups, with average mutation rates of 2.7% and 0.5% for ALD and
CC samples, respectively. No signiﬁcant differences in substitution
numbers between genotype B andCwere observed in each group.
A U-shaped distribution of fm/quasi and more
substitutions in ALDs
We found a distinctive U-shaped distribution pattern of fm/quasi
with either high (80%) or low values (20%) (Fig. 2A). The
majority of mutations, 86% in ALD and 92% in CC groups, fellClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectwithin these two categories. In CC subjects, the number of
mutations with high fm/quasi was more than that of mutations with
low fm/quasi (749 vs. 612); while mutations with low fm/quasi in ALD
group were nearly three times more than those with high fm/quasi
(1714 vs. 459). For substitutions with high fm/quasi, some were
common among samples. For instance, 20 and 14 loci were
mutated in over 25% of patients in ALD and CC groups,
respectively, of which 10 were shared by both groups, and most
(67%) of these commonly high fm/quasi substitutions were syn-
onymous (Fig. 2B).
When comparing mutations between ALD and CC groups,
we analyzed mutations with fm/quasi higher than 5% in samples
with all nucleotide coverage165 based on the above hyperbola
model (Supplementary Fig. 1A). Substitutions in ALD samples
were two times of those in CC ones (70 ± 28 vs. 31 ± 10, p =
0.001, t test). Patients in two groups had similar amounts of viral
mutations with fm/quasi larger than 80% (p = 0.196), but ALD
patients had signiﬁcantly more substitutions with low fm/quasi (
20%) (p = 0.006). Furthermore, substitutions observed in ALD
samples had much higher nonsynonymous/synonymous ratio,
especially in the preS/S (p <0.001) region.
A spectrum of candidate substitutions associated with
liver disease progression
To identify viral factors correlating to the disease progression,
fm/quasi values of all point mutations were compared between
ALD and CC groups with a cutoff of no less than 5% for each
site. Ten substitutions were identiﬁed (p <0.05), including
G1764A, A1762T, G1896A, G1613A, A2189C/T, A1846T,
C1653T, A/G2525C/T, C2304A, and C2288A/T (Fig. 3A).
Especially, almost all ALD samples had high fm/quasi for 1762(T)/
1764(A) substitutions, although one CC patient (sample 30)
also had this double mutation with fm/quasi over 90%.
Among these 10 candidate substitutions, except for A/
G2525C/T in P gene, all the rest were in preC/C and X genes
(Fig. 3B). In addition to seven mutations previously reported
[4,16–18], C2288A/T, C2304A, and A/G2525C/T were iden-
tiﬁed for the ﬁrst time to correlate to severe liver disease.
C2288A/T and C2304A lead to amino acid changes as P130T/S
and P135Q in C protein, and A/G2525C/T leads to K73N/E73D
of P protein. With the average fm/quasi of 64%, 65%, and 73%,
respectively, C2288A/T, C2304A, and A/G2525C/T were seen
in nearly half of ALD patients. Interestingly, these three sub-
stitutions all lie in the large HBsAg promoter region and may
affect the binding of host factors revealed by transcription
factor binding analysis (Supplementary Table 2).
Distinct deletion patterns between ALD and CC groups
In total, 50 deletions in ALD and 21 in CC samples were
resolved (Fig. 4), and most of them were in-frame (79%). Aious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 280–287
FIG. 1. The distribution of total substitutions along the hepatitis B virus (HBV) genome and their frequencies within quasispecies. Circles, from outside
in, showed a) the nucleotide position and four genes in the HBV genome; b) the average values of fm/quasi in mutation-containing subjects; c) the
mutation rate in each 9-bp window shown as green-red colour scale at one base sliding step; d) the average sequencing coverage at each site; e)
substitutions and their fm/quasi shown as green-red colour scale in each individual samples (grey semi-circles). Left half, samples with advanced liver
disease (ALD); right half, chronic carriers (CC).
CMI Li et al. Characterization of HBV quasispecies 283majority of deletions (80%) were no more than 20% within
quasispecies (fm/quasi 20%), but some preS and X deletion
variants had fm/quasi around 36% and 58%, respectively. We
chose X deletions in Sample 15 of the CC group for deletion
veriﬁcation, and all three variants were veriﬁed by clone
sequencing.
Each clinical group seems to have its unique deletion pattern.
Most deletions in ALD samples were located in preS (n = 41);
however, for CC samples, 11 of 21 deletions were in the X
gene (Fig. 4). In particular, ALD samples had most of their
deletions located in the preS2 region (34 of 41 preS deletions;
83%), whereas CC samples had only preS1 deletions detected.
Finally, most deletions interrupted B- or T-cell epitopes, but no
epitopes were disrupted by preS deletions in young CC samplesClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology(Supplementary Table 3), implying the late attack by immune
system during the infection.DiscussionThe landscapes of viral mutations revealed by deep
sequencing
Our data demonstrated a comprehensive picture of viral qua-
sispecies in relatively large samples. On average, 157 sub-
stitutions were identiﬁed in ALD samples (Supplementary
Table 1), which is much higher than 45–80 as reported pre-
viously [16,19]. For proﬁling mutation patterns in an early state
of infection, we enrolled young patients of the CC group. CCand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 280–287
FIG. 2. A U-shaped distribution of fm/quasi and common substitutions with fm/quasi 80% in both chronic carriers (CC) and advanced liver disease
(ALD) samples. (A) The great majority of fm/quasi values were clustered in high (80%) or low (20%) category for all samples. Numbers on the top of
each bar are the actual mutant number of corresponding fm/quasi. (B) Among ten common substitutions with high fm/quasi shared by the two groups
(red), only one is nonsynonymous (star). Five common mutations with fm/quasi 80% in the ALD group are identiﬁed to associate with liver disease
progression (bold letters). Green-red colour scale, percentage of mutation containing samples in each group. *Nonsynonymous mutations.
284 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIsubjects had less complicated quasispecies, and showed dra-
matic difference in the most variable regions and deletion pat-
terns with ALD subjects, providing clues for selection pressures
in early and late stages during the chronic infection.
The most characteristic feature of deep sequencing is its
“one shot for all” on mutation discovery and proﬁling. For the
ﬁrst time we discovered a U-shaped distribution of fm/quasi for
HBV substitutions in individual samples (Fig. 2A), which was
consistently observed in our recent study on IonTorrent PGM
platform (Life Technologies, Grand Island, NY, USA)
(Supplementary Fig. 1B). Signiﬁcantly more variants with low fm/
quasi (20%) in the ALD group (Fig. 2A) may result from two
aspects. First, these mutations may have occurred recently with
insufﬁcient time to accumulate. Second, some mutations,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectbeneﬁcial in the early stage, decreased to a low level in the
current changed host environment. For example, drug-resistant
mutations were still observed in two ALD individuals even
though the patients were under no treatment at the time of
sample collection (Supplementary Text for detailed description
of drug-resistant mutations). Similar persistence of drug-
resistant mutations was also reported in previous HIV pyro-
sequencing studies [20].
From our observations, the fm/quasi among samples varies
greatly even from the same clinical group, and this may reduce
the power of traditional designs to detect substitutions related
to disease progression. Deep sequencing strategy improved the
sensitivity to detect viral variants, and here we reported 10
substitutions across the whole genome very likely correlating toious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 280–287
FIG. 3. Ten substitutions signiﬁcantly associated with advanced liver disease (ALD). (A) The heat map showing fm/quasi of mutations by blue-red colour
scale in each of ALD and chronic carriers (CC) samples in the order of p values of Kolmogorov-Smirnov test. Samples with the coverage lower than
165 were depicted as grey. (B) The location of these 10 substitutions in the hepatitis B virus (HBV) genome. Four genes and related regulatory regions
were presented by grey and black bars, respectively.
CMI Li et al. Characterization of HBV quasispecies 285ALD (Fig. 3A), including seven well-known mutations and three
novel ones (see below).
Mutations correlating to severe liver diseases
Three mutations (C2288A/T, C2304A, and A/G2525C/T) were
shown for the ﬁrst time to correlate with the disease progres-
sion. Among these, both C2288A/T (P130T/S) and C2304A
(P135Q), located in the hypervariable region covering aa130-135
of C protein [21], would interrupt epitopes recognized by B or T
cells [22,23]. Moreover, the change of proline is likely to affect C
protein structure [24], indicating their possible roles in viral
escape from immune surveillance. The A/G2525C/T in the preS1
promoter is predicted to introduce additional binding sites to
NF-1 and liver-speciﬁc transcription factor C/EBPα, suggesting
higher production of large HBsAg, which may contribute to ALD
[25]. In addition to the above 10 mutations identiﬁed using both
K S and M W test, a group of substitutions also have signals by
single test, and some of them were also reported previously,
such as T1753C/A, G1899A, and T53C [26]. Certainly the
veriﬁcation for all candidates in larger samples and longitudinal
studies is needed.
PreS2 deleted strains are deleterious in liver disease progres-
sion [6]. This research shows that preS2 deletion was not
detected in CC samples even by deep sequencing, suggesting thatClinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologypreS2 deletions may not occur before 18 years of age in vertical
transmission cases, although preS1 deletions and certain common
substitutions such as A1762T and G1764A may have emerged at
this stage. It should be mentioned that all deleted variants coex-
isted with the wild-type strains, suggesting the enhanced viral
adaptation by co-existence of wild-type and deleted variants [27].
In conclusion, by massively parallel pyrosequencing in two
groups of ALD and CC samples, we were able to reveal the full
landscapes of HBV mutations in individual patients. A spectrum
of mutations, including three novel substitutions, was found to
associate with liver disease progression. Our results indicated
that preS2 deletions hardly occurred before 18 years of age.
Furthermore, a unique U-shaped distribution of fm/quasi was
resolved in both groups, but signiﬁcantly more substitutions with
low fm/quasi were detected in the ALD group. These results also
show that deep sequencing is an efﬁcient approach to charac-
terize HBV quasispecies and its correlations to clinical outcomes.Transparency declarationThis work was supported by the National Natural Science
Foundation of China (grant number 81071649, 81201700) and
Science and Technology Major Projects of “AIDS and viraland Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 280–287
FIG. 4. Distinct deletion patterns of PreS, X, and Core regions. In the advanced liver disease (ALD) group, the 5’ terminus of preS2 was most commonly
deleted, and nearly half of such deletions (16 of 34) ended at aa141. Each observed deletion was presented as various sizes of black blocks in corre-
sponding genes in the ALD (deep blue) and chronic carrier (CC) samples (light blue). Deletions from the same individual were framed by solid black lines
with the ID number on the left. Scaled red bars at the right of each deletion indicate its fm/quasi. The vertical black dashed line separates preS1 and preS2.
286 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIhepatitis prevention and treatment of major infectious diseases”
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